MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, BEIGF made $5,343,033K in revenue. $286,933K in net income. Net profit margin of 5.37%.

Income Overview

Revenue
$5,343,033K
Net Income
$286,933K
Net Profit Margin
5.37%
EPS
$0.19
Unit: Thousand (K) dollars
Revenue Breakdown
    • BRUKINSA
    • Tislelizumab
    • XGEVA
    • Others
Revenue Breakdown
    • US
    • CN
    • Europe
    • All Other Countries Except China...

Income Statement
2025-12-31
2024-12-31
Total revenues
5,343,033 3,779,546
Cost of sales - product
-594,089
Cost of sales - product-Product
668,540 -
Gross profit
4,674,493 3,216,152
Research and development
2,145,868 1,953,295
Selling, general and administrative
2,081,489 1,831,056
Total operating expenses
4,227,357 3,784,351
Income (loss) from operations
447,136 -568,199
Interest income
70,505 -
Interest expense
58,234 -
Other (expense) income, net
-42,553 -12,638
Interest income, net
-47,836
Income (loss) before income taxes
416,854 -533,001
Income tax expense
129,921 111,785
Net income (loss)
286,933 -644,786
Basic EPS
0.2 -0.47
Diluted EPS
0.19 -0.47
Basic Average Shares
1,417,803,727 1,368,746,793
Diluted Average Shares
1,474,829,908 1,368,746,793
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
BRUKINSA$3,928,489K (48.57%↑ Y/Y)Tislelizumab$737,304K (18.76%↑ Y/Y)XGEVA$305,979K (36.35%↑ Y/Y)BLINCYTO$104,224K (40.22%↑ Y/Y)Other$83,691K (39.39%↑ Y/Y)KYPROLIS$74,974K (13.30%↑ Y/Y)Pobevcy$47,400K (-11.42%↓ Y/Y)Amgen Royalty Revenue$40,733K Novartis Broad MarketsRevenue$17,598K Collaboration Other$2,641K Product$5,282,061K (1369.25%↑ Y/Y)Collaboration$60,972K (1854.86%↑ Y/Y)Total revenues$5,343,033K (41.37%↑ Y/Y)Gross profit$4,674,493K (45.34%↑ Y/Y)Cost of sales -product-Product$668,540K Income (loss) fromoperations$447,136K (178.69%↑ Y/Y)Interest income$70,505K Total operatingexpenses$4,227,357K (11.71%↑ Y/Y)Income (loss) beforeincome taxes$416,854K (178.21%↑ Y/Y)Interest expense$58,234K Other (expense)income, net-$42,553K (-236.71%↓ Y/Y)Research and development$2,145,868K (9.86%↑ Y/Y)Selling, general andadministrative$2,081,489K (13.68%↑ Y/Y)Net income (loss)$286,933K (144.50%↑ Y/Y)Income tax expense$129,921K (16.22%↑ Y/Y)

BeOne Medicines Ltd. (BEIGF)

BeOne Medicines Ltd. (BEIGF)